Doctors and researchers at the University of Nebraska Medical Center are hoping to bring a different therapy that uses a ...

AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living ...

The Sickle Cell Society described the decision to withdraw its European marketing authorisation as a significant setback for patients. Vertex's gene-editing therapy for sickle cell disease ...

New CAR-T Cell Therapy ... sickle cell disease, according to results of a trial completed at about 20 cancer ... Feb. 7, 2025 — A research team has made a major discovery on how the CUL5 gene ...

Kevyn L Hart, Boya Liu, Devin Brown, Beatriz Campo-Fernandez, Kevin Tam, Katherine Orr, Roger P Hollis, Christian Brendel, David A Williams, Donald B Kohn A major limitation of gene therapy for sickle ...